United Therapeutics
UTHR
320 hedge funds and large institutions have $3.63B invested in United Therapeutics in 2019 Q4 according to their latest regulatory filings, with 66 funds opening new positions, 103 increasing their positions, 94 reducing their positions, and 41 closing their positions.
61% more first-time investments, than exits
New positions opened: 66 | Existing positions closed: 41
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
10% more capital invested
Capital invested by funds: $3.3B → $3.63B (+$331M)
6% more funds holding
Funds holding: 302 → 320 (+18)
10% more repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 94
5% more call options, than puts
Call options by funds: $23.6M | Put options by funds: $22.5M
0.38% less ownership
Funds ownership: 94.33% → 93.94% (-0.38%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$44M |
| 2 |
Renaissance Technologies
New York
|
+$29.2M |
| 3 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
+$20.1M |
| 4 |
BlackRock
New York
|
+$19.3M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$51.1M |
| 2 |
Millennium Management
New York
|
-$49.5M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$31.9M |
| 4 |
WG
Winton Group
London,
United Kingdom
|
-$21.6M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$20.1M |
UTHR Hedge Fund Activity: Q4 2019 in Review
320 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q4 2019, worth a combined $3.63B — up 10% from $3.3B a quarter earlier.
Buyers outnumbered sellers: 66 funds opened new UTHR positions and 41 closed out — a net gain of 25 holders — while 103 added to existing stakes and 94 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $44M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $51.1M sold.
- 320 institutional investors held United Therapeutics (UTHR) as of Q4 2019, up from 302 in Q3 2019.
- Funds reported $3.63B of United Therapeutics stock for Q4 2019, up 10% quarter-over-quarter.
- 66 funds opened new United Therapeutics positions in Q4 2019 and 41 closed out, a net change of +25 holders.
- The largest United Therapeutics buyer in Q4 2019 was Adage Capital Partners, an estimated $44M added.
- The largest United Therapeutics seller in Q4 2019 was Point72 Asset Management, an estimated $51.1M sold.
Based on aggregated 13F filings for Q4 2019.